Gynecologic OncologyArchives
Cannabidiol as a novel therapeutic agent in breast cancer: evidence from literature
Gynecologic Oncology 4 min.
Breast cancer is one of the most prevalent malignancies among women worldwide, characterized by its heterogeneity and diverse subtypes, each requiring distinct therapeutic strategies [1]. Despite significant advancements in treatment modalities, challenges persist, including resistance to existing therapies...
Adjuvant ovarian function suppression in premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2–negative early breast cancer: a multi-center retrospective study
Gynecologic Oncology 4 min.
As early as 2000, in-depth molecular research ushered breast cancer into an era of classification and targeted treatment. Approximately 75% of early breast cancers are hormone receptor-positive (HR+) subtype, requiring adjuvant endocrine therapy [1]. Tamoxifen is the first adjuvant regimen for premenopausal...
A systematic review and meta-analysis of pregnancy-associated breast cancer incidence rate
Gynecologic Oncology 5 min.
Pregnancy-Associated Breast Cancer (PABC) is a special type of breast cancer that occurs either during pregnancy or within 1 year postpartum [1, 2–3]. However, the period of time by which pregnancy-related breast cancer is defined varies among studies, ranging from 1 year after pregnancy in some...
HLA class II-restricted T cell epitopes in public neoantigens of ESR1 and PIK3CA in breast cancer
Gynecologic Oncology 6 min.
Breast cancer is the leading cause of cancer-related deaths worldwide [1]. Hormone receptor-positive (HR +) breast cancer accounts for approximately 70% of all cases of breast cancer [2]. Despite advances in endocrine therapies, treatment resistance remains a challenge, resulting in limited treatment...
